CSF1R inhibitors are a potential AD therapeutic and prevent AD-associated microgliosis by blocking the CSF1R/PU.1 survival signalling pathway33–36 but the impact on peripheral macrophages has not been reported. Here, SPI1 is linked to Alzheimer disease.